Blog
RSS FeedPosted by Michael Wonder on 08 Feb 2024
Knight Therapeutics announces launch of Bijuva in Canada
6 February 2024 - Knight Therapeutics announced today the launch of Bijuva (oestradiol and progesterone) capsules in Canada. ...
Posted by Michael Wonder on 08 Feb 2024
HLS announces that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan
6 February 2024 - Public reimbursement for Vascepa is now available in Ontario, Quebec, British Columbia, Saskatchewan, New Brunswick, Northwest Territories, ...
Posted by Michael Wonder on 05 Feb 2024
Sumitomo Pharma and Pfizer Canada announce availability of Myfembree in Canada
31 January 2024 - In partnership with Sumitomo, Pfizer is proud to announce that supply of Myfembree (relugolix 40 mg, estradiol ...
Posted by Michael Wonder on 18 Jan 2024
Sudbury, Ontario family finally gets coverage for drug to treat daughter's rare epilepsy
16 January 2024 - Fenfluramine costs more than $3,000 a month and is not approved by Health Canada. ...
Posted by Michael Wonder on 22 Dec 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) receive public listing for patients with advanced endometrial carcinoma that is not MSI-H or dMMR
21 December 2023 - Merck and Eisai announce that Keytruda plus Lenvima, is now reimbursed with clinical criteria and conditions ...
Posted by Michael Wonder on 19 Dec 2023
The Government of Canada announces the creation of the Canadian Drug Agency
18 December 2023 - Helping make Canada's drug system more sustainable and better prepared for the future. ...
Posted by Michael Wonder on 30 Nov 2023
Prevalence and nature of manufacturer-sponsored patient support programs for prescription drugs in Canada: a cross-sectional study
27 November 2023 - Of the 2556 prescription drugs marketed by 89 companies in the study period, 256 (10.0%) had a ...
Posted by Michael Wonder on 13 Nov 2023
Informing real-time decisions with post-market drug evidence
10 November 2023 - It’s been one year since CADTH launched the Post-Market Drug Evaluation (PMDE) Program to provide decision-makers with ...
Posted by Michael Wonder on 08 Nov 2023
Mitsubishi Tanabe Pharma Canada announces that Company's oral treatment formulation for amyotrophic lateral sclerosis has been added to the provincial drug plans in Prince Edward Island, Newfoundland and Labrador
7 November 2023 - Mitsubishi Tanabe Pharma Canada today announced that Radicava oral suspension (edaravone) is now covered under the Prince ...
Posted by Michael Wonder on 02 Nov 2023
Rhythm Pharmaceuticals receives positive CADTH reimbursement recommendation for Imcivree (setmelanotide)
2 November 2023 - Recommendation based on demonstrated clinical benefit in Phase 3 trial. ...
Posted by Michael Wonder on 27 Oct 2023
Drugs are outrageously expensive—Canada found a way to fight back
27 October 2023 - Latuda is a drug to treat schizophrenia. It costs about $4,000 per month in the US. ...
Posted by Michael Wonder on 26 Oct 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) is available for the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma
25 October 2023 - Merck and Eisai announced today that Keytruda, an anti-PD-1 therapy, in combination with Lenvima, the multiple receptor ...
Posted by Michael Wonder on 14 Oct 2023
Government of Canada announces new appointment to the Patented Medicine Prices Review Board
12 October 2023 - Today, the Honourable Mark Holland, Minister of Health, announced a new appointment to the Patented Medicine Prices ...
Posted by Michael Wonder on 30 Sep 2023
Medison Pharma announces public formulary listing of Qinlock (ripretinib) in Canadian provinces: Ontario and Quebec for advanced gastro-intestinal stromal tumour treatment
29 September 2023 - Medison Pharma is pleased to announce the public formulary listing of Qinlock in Canadian provinces: Ontario ...
Posted by Michael Wonder on 22 Sep 2023
PMPRB report shows increased plan costs, promising pharmaceutical innovation: expert
20 September 2023 - A recent report by the Patented Medicine Prices Review Board shows increased growth for private drug ...